An Indiana-based pharmaceutical firm announced Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among long-term care facility residents and staff.
Eli Lilly and Company confirmed the Phase 3 BLAZE-2 COVID-19 prevention trial results suggest that residents randomized to bamlanivimab have up to an 80 percent lower risk of contracting COVID-19 versus residents in the same facility randomized to placebo.
Read More
